Answers are grounded in this paper and cite their sources.
Randomized trial demonstrates improved disease-free survival in high-risk endometrial cancer, suggesting combined therapy benefits.
e17635 Background: The survival benefit of adjuvant chemoradiotherapy compared with radiotherapy alone in high-risk endometrial cancer (EC) remains debated. With updated PORTEC-3 results and maturation of earlier randomized clinical trials (RCTs), a contemporary quantitative reassessment is warranted. Methods: A PRISMA-compliant systematic review and meta-analysis of RCTs compared adjuvant chemoradiotherapy versus radiotherapy alone after surgery in high-risk EC. Kaplan–Meier curves were digitized using ScanIt, and individual patient data were reconstructed with IPDfromKM, with validation by log-rank test, root mean square error, and Kolmogorov–Smirnov test. Overall survival (OS) and disease-free survival (DFS) were pooled using random-effects models and expressed as hazard ratios (HRs) with 95% CIs. Trial-level weighted meta-regressions explored effect modification by FIGO stage, histologic subtype, tumor grade, and extent of lymphadenectomy. Safety outcomes were summarized using pooled risk ratios (RRs). Results: Six RCTs including 2,105 patients were analyzed, with OS effects ranging from negative in earlier trials to improved survival in contemporary combined-modality studies. In pooled analysis, chemoradiotherapy was associated with a borderline improvement in OS (HR 0.83, 95% CI 0.69–1.01; p=0.06; I²=0%). DFS was consistently improved with chemoradiotherapy across trials, yielding a statistically significant pooled benefit (HR 0.75, 95% CI 0.63–0.91; p<0.01; I²=0%). Trial-specific DFS HRs ranged from approximately 0.60 to 0.85, favoring combined treatment in the majority of comparisons, including PORTEC-3–eligible populations. Meta-regression analyses demonstrated limited explanatory power for OS according to FIGO stage I–III, tumor grade, or non-endometrioid histology, with low coefficients of determination across models (R²≤0.31). In contrast, DFS benefit showed a strong association with extent of lymphadenectomy (R²=0.85), suggesting greater relative benefit in comprehensively staged patients. Chemoradiotherapy increased acute grade ≥3 hematologic and gastrointestinal toxicity compared with radiotherapy alone, while late grade ≥3 adverse events were infrequent and similar between groups. Conclusions: In high-risk EC, adjuvant chemoradiotherapy significantly improves DFS and confers a borderline OS benefit compared with radiotherapy alone, with acceptable long-term toxicity. The magnitude of benefit appears more closely related to surgical staging quality than to histology or tumor grade, supporting combined-modality therapy in selected patients.
No takes yet. Share an insight, caveat, or question.
Melo et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: